AMC ENTERTAINMENT HOLDINGS, INC. vs Bristol-Myers Squibb Co — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.49 (market cap $2.14B), while Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 60.7× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| AMC | BMY | |
|---|---|---|
Market Cap | $2.14B | $129.94B |
Sector | Media | Health |
52-Week High | $3.15 | $65.89 |
52-Week Low | $0.95 | $42.60 |
Enterprise Value | $9.08B | $163.92B |
Dividend Yield | 0.11% | 3.96% |
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.465, up 1.86% on the day, with a bullish technical signal and recent earnings beats. The company reported record revenue and EBITDA in Q2 2026, with improving cash flow trends. However, it remains unprofitable with a net income margin of -10.59% and negative shareholder equity of -$1.76 billion. Analyst consensus is mixed with a $3.00 price target.
Outlook hinges on sustained box office recovery and cost discipline to achieve profitability. Key risks include high debt load, competitive pressures, and reliance on blockbuster films. Upside potential exists if operational improvements continue, but financial stability remains a concern for investors.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
Latest headlines on both assets
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →